AKBA 8-K: SEC filing
Akebia Therapeutics
Filed with the SEC on · accession 0001517022-26-000083
AKBA filed a 8-K (current report) with the SEC on Nov 5, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -38.8% by the first close after the filing.
Summary of the filing
Akebia Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, along with recent business highlights.
Key details
How AKBA stock reacted
Close before
$0.69
Nov 4, 2026
First close after
-38.75%
$0.43
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for AKBA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AKBA?
Click hereFrequently asked questions
What did AKBA file with the SEC on Nov 5, 2026?
AKBA filed a 8-K (SEC filing). Akebia Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, along with recent business highlights.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did AKBA stock react to this filing?
AKBA closed at $0.69 before the filing and $0.43 on Nov 5, 2026 (-38.75%).
Other AKBA SEC filings
- 10-Q · SEC filingNov 5, 2026
- 8-K · Delisting noticeOct 23, 2026
- 8-K · Executive departureOct 14, 2026
- 8-K · SEC filingAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · Fda approvalJun 30, 2026
- 144 · Insider sale plannedJun 29, 2026
- 8-K · Board changeJun 22, 2026
- 10-Q · SEC filingMay 7, 2026
- 8-K · SEC filingMay 7, 2026
Get alerts when AKBA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days